Glaxosmithkline Pharmaceuticals Ltd
Glaxosmithkline Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company aims for a 12%-14% CAGR over the next 5-7 years, targeting to double revenue from FY24 baseline. GlaxoSmithKline Pharmaceuticals aims to sustain EBITDA margins rather than expand, focusing on consistent performance and competitive positioning.
From Glaxosmithkline Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company aims for a 12%-14% CAGR over the next 5-7 years, targeting to double revenue from FY24 baseline.
- Base GenMed and established vaccines are expected to grow at high single digits (8%-10%) over the next 5 years.
- Specialty and super-specialty portfolios, including oncology and new vaccine launches like Shingrix and RSV, are expected to boost growth, contributing 10%-15% of topline initially, potentially increasing to 20%-25% over 5-7 years.
- Supply chain issues impacting growth have been resolved, allowing normalization and resumption of targeted growth rates.
- Fresh product launches, especially in oncology and vaccines, are drivers of accelerated sales growth alongside sustaining margins.
- The company expects sustained double-digit growth in the vaccine business for at least six consecutive quarters.
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Glaxosmithkline Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No specific mention of current or future capital expenditure (capex) or strategic investments on page 18 of the document.
- Focus is primarily on product launches, pipeline innovations, and supply chain agility rather than explicit capex plans.
- Investments are implied in areas like specialty and super-specialty portfolios requiring agile supply chains.
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Glaxosmithkline Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Glaxosmithkline Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Glaxosmithkline Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹995 Cr, net profit ₹278 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glaxosmithkline Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Glaxosmithkline Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Glaxosmithkline Pharmaceuticals Ltd Q3 FY26 results?
The company aims for a 12%-14% CAGR over the next 5-7 years, targeting to double revenue from FY24 baseline. GlaxoSmithKline Pharmaceuticals aims to sustain EBITDA margins rather than expand, focusing on consistent performance and competitive positioning.
What is Glaxosmithkline Pharmaceuticals Ltd share price analysis?
Glaxosmithkline Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 43.3 with a market cap of ₹45,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glaxosmithkline Pharmaceuticals Ltd planning capital expenditure?
No specific mention of current or future capital expenditure (capex) or strategic investments on page 18 of the document.
Keep Glaxosmithkline Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.